<div class="headers"><div>Fig. 3 (A) Mean ( s.e.) change from baseline to end-point in haemoglobin A1c (HbA1c) in patients aged <65 years (open bars; n ¼ 91, 97 and 106; mean baseline HbA1c  8.6% for all treatment groups) and in patients aged 65 years (closed bars; n ¼ 41, 35 and 38; mean baseline HbA1c ¼ 8.5, 8.2 and 8.5% for vildagliptin 50 mg daily, 100 mg daily or placebo respectively). (B) Mean ( s.e.) change from baseline to end-point in HbA1c in patients with lower baseline HbA1c (open bars; n ¼ 100, 93 and 99; mean baseline HbA1c  8.0% for all treatment groups) and in patients with higher baseline HbA1c (closed bars; n ¼ 32, 39 and 45; mean baseline HbA1c ¼ 9.8% for all treatments).</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p class="">Fig. 3 (A) Mean ( s.e.) change from baseline to end-point in haemoglobin A1c (HbA1c) in patients aged <65 years (open bars; n ¼ 91, 97 and 106; mean baseline HbA1c  8.6% for all treatment groups) and in patients aged 65 years (closed bars; n ¼ 41, 35 and 38; mean baseline HbA1c ¼ 8.5, 8.2 and 8.5% for vildagliptin 50 mg daily, 100 mg daily or placebo respectively). (B) Mean ( s.e.) change from baseline to end-point in HbA1c in patients with lower baseline HbA1c (open bars; n ¼ 100, 93 and 99; mean baseline HbA1c  8.0% for all treatment groups) and in patients with higher baseline HbA1c (closed bars; n ¼ 32, 39 and 45; mean baseline HbA1c ¼ 9.8% for all treatments).</p></td>
</tr>
</tbody>
</table>
